FDA: Slightly elevated risk of cardiovascular, cerebrovascular with Xolair

An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug omalizumab (Xolair, Genentech) than in those who were not treated with omalizumab. As a result, FDA has added information about these potential risks to the drug label.
» Read more about this "niche" drug

Humira receives FDA approval for treating pediatric patients with Crohn's disease

FDA has approved adalimubab (Humira, AbbVie) to treat pediatric patients with moderate to severe Crohn's disease.
» Crohn's can present at any age; read more

Continuing Education

MTM essentials for anticoagulant management in cardiovascular disease

This month's article is the seventh in a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to review the pharmacological properties, safety and efficacy, and risk/benefit profile for the various anticoagulant medications used in cardiovascular diseases.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT10-VXP89.

Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

Revitalizing stagnant sepsis pipeline requires targeting niche patient populations, with premium pricing likely justified

The sepsis marketplace has been one of high unmet medical need for decades and needs more novel therapies. » See more

• Tiotropium for asthma: Appears to be effective adjunct in phase 3 studies

• FDA approves treatment for ulcerative colitis and Crohn's

RESOURCES

Latest Clinical News